<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571645</url>
  </required_header>
  <id_info>
    <org_study_id>CMX-DS-003</org_study_id>
    <nct_id>NCT04571645</nct_id>
  </id_info>
  <brief_title>Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly&#xD;
      diagnosed untreated AML with adverse or intermediate genetic risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to&#xD;
      evaluate the efficacy and safety of dociparstat sodium in combination with standard intensive&#xD;
      induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Measured from randomization up to 5 years</time_frame>
    <description>Overall survival is defined as time until death from any cause, through 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Measured from randomization up to 5 years</time_frame>
    <description>Event free survival (EFS) is defined as time to induction/reinduction treatment failure (within 42 days), relapse after complete remission (CR), or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dociparstat sodium (DSTAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dociparastat sodium</intervention_name>
    <description>Dociparstat is a glycosaminoglycan derived from porcine heparin.</description>
    <arm_group_label>Dociparstat sodium (DSTAT)</arm_group_label>
    <other_name>DSTAT</other_name>
    <other_name>CX-01</other_name>
    <other_name>2-0,3-0 desulfated heparin</other_name>
    <other_name>ODSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Normal Saline</other_name>
    <other_name>Normal saline</other_name>
    <other_name>Sodium chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed, previously untreated AML (according to World Health Organization&#xD;
             criteria) with at least 20% blasts in the peripheral blood or bone marrow.&#xD;
&#xD;
          2. Age 18 to &lt;60 years with adverse genetic risk, OR Age &gt;=60 with intermediate or&#xD;
             adverse genetic risk (according to ELN criteria).&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 if ≤79 years of&#xD;
             age; ECOG status of 0 or 1 if ≥80 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia (t(15;17)), myeloid sarcoma without bone marrow&#xD;
             involvement, or blast transformation of chronic myelogenous leukemia.&#xD;
&#xD;
          2. AML with a history of antecedent myelodysplasia that has been previously-treated&#xD;
             (e.g., with a hypomethylating agent).&#xD;
&#xD;
          3. Therapy-related AML after prior radiotherapy or chemotherapy for another cancer or&#xD;
             disorder.&#xD;
&#xD;
          4. Clinical evidence of active central nervous system leukemia.&#xD;
&#xD;
          5. AML treatment, including Vyxeos (CPX-351, liposomal cytarabine and daunorubicin),&#xD;
             gemtuzumab ozogamicin, or any other prohibited concomitant AML therapy previously&#xD;
             received or anticipated to start during the study.&#xD;
&#xD;
          6. Receiving any form of anticoagulant therapy (e.g., unfractionated heparin, low&#xD;
             molecular weight heparin, coumadin, factor Xa inhibitors). Heparin flush of indwelling&#xD;
             catheters is permitted.&#xD;
&#xD;
          7. Treatment with any other investigational agent within 28 days, or 5 half-lives,&#xD;
             whichever is longer, prior to baseline.&#xD;
&#xD;
          8. Any major surgery or radiation therapy within 28 days prior to baseline.&#xD;
&#xD;
          9. Immediately life threatening, severe complications of leukemia such as pneumonia with&#xD;
             hypoxia or shock, and/or disseminated intravascular coagulation.&#xD;
&#xD;
         10. Active or uncontrolled bleeding at the time of randomization; a bleeding disorder,&#xD;
             either inherited or caused by disease; history of known arterial-venous malformation,&#xD;
             intracranial hemorrhage, or suspected or known cerebral aneurysm; or clinically&#xD;
             significant gastrointestinal bleeding within the 3 weeks prior to randomization.&#xD;
&#xD;
         11. Presence of significant active or uncontrolled infection, including HIV or hepatitis B&#xD;
             or C.&#xD;
&#xD;
         12. Active (uncontrolled, metastatic) second malignancy.&#xD;
&#xD;
         13. History of severe congestive heart failure or other cardiac disease that&#xD;
             contraindicates the use of idarubicin or daunorubicin (e.g., cardiac ejection fraction&#xD;
             &lt;45%).&#xD;
&#xD;
         14. QTc &gt;450 msec for a male, &gt;470 msec for a female, or &gt;480 msec if underlying bundle&#xD;
             branch block.&#xD;
&#xD;
         15. Severe renal impairment, as determined by calculated creatinine clearance &lt;30 mL/min&#xD;
             or estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m2.&#xD;
&#xD;
         16. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3x upper limit of&#xD;
             normal (ULN) or total bilirubin &gt;2x ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion Morrison, MD</last_name>
    <phone>919.313.2977</phone>
    <email>mmorrison@chimerix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Yarber</last_name>
    <phone>919-886-1140</phone>
    <email>eyarber@chimerix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Norton Cancer Institute, St. Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Stevens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allina Health System / Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Tsai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nashat Gabrail, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Shami, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

